Abbvie Inc (NYSE:ABBV)’s traded shares stood at 5.07 million during the last session, with the company’s beta value hitting 0.56. At the close of trading, the stock’s price was $180.35, to imply an increase of 0.65% or $1.16 in intraday trading. The ABBV share’s 52-week high remains $182.89, putting it -1.41% down since that peak but still an impressive 27.39% since price per share fell to its 52-week low of $130.96. The company has a valuation of $318.58B, with an average of 7.51 million shares in intraday trading volume over the past 10 days and average of 5.60 million shares over the past 3 months.
Abbvie Inc (NYSE:ABBV) trade information
After registering a 0.65% upside in the last session, Abbvie Inc (ABBV) has traded red over the past five days. The stock hit a weekly high of 180.58, jumping 0.65% in its intraday price action. The 5-day price performance for the stock is 2.31%, and 0.76% over 30 days. With these gigs, the year-to-date price performance is 16.38%. Short interest in Abbvie Inc (NYSE:ABBV) saw shorts transact 14.27 million shares and set a 2.75 days time to cover.
Abbvie Inc (ABBV) estimates and forecasts
Looking at statistics comparing Abbvie Inc share performance against respective industry, we note that the company has underperformed competitors. Abbvie Inc (ABBV) shares are 17.18% up over the last 6 months, with its year-to-date growth rate lower than industry average at 0.45% against 4.40%. Revenue is forecast to shrink -5.30% this quarter before falling -3.80% for the next one. The rating firms project that company’s revenue will grow 0.40% compared to the previous financial year.
Revenue forecast for the current quarter as set by 14 analysts is $11.97 billion. Meanwhile, for the quarter ending Jun 2024, a total of 14 analyst(s) estimate revenue growth to $13.52 billion.Earnings reports from the last fiscal year show that sales brought in $12.22 billion and $13.87 billion respectively in the corresponding quarters. In this case, analysts estimate current quarter sales to fall -2.10% before dropping -2.50% in the following quarter.
An assessment of the company’s 5-year growth patterns shows that annual earnings shrunk an estimated -5.77% for the past 5-year period. While 2024 is set for a 0.62% return in earnings, projections for the next 5 years are at 3.71% annually.
ABBV Dividends
Abbvie Inc has its next earnings report out between April 25 and April 29. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too. Abbvie Inc has a forward dividend ratio of 5.99, with the share yield ticking at 3.32% to continue the rising pattern observed over the past year. The company’s average dividend yield trailing the past 5-year period is 0.00%.
Abbvie Inc (NYSE:ABBV)’s Major holders
Abbvie Inc insiders hold 0.12% of total outstanding shares, with institutional holders owning 71.89% of the shares at 71.98% float percentage. In total, 71.89% institutions holds shares in the company, led by Vanguard Group Inc. As of Jun 29, 2023, the company held over 159.3 million shares (or 9.03% of shares), all amounting to roughly $21.46 billion.
The next major institution holding the largest number of shares is Blackrock Inc. with 139.16 million shares, or about 7.88% of shares outstanding. As of the market price on Jun 29, 2023, these shares were worth $18.75 billion.
We also have Vanguard Total Stock Market Index Fund and Vanguard 500 Index Fund as the top two Mutual Funds with the largest holdings of the Abbvie Inc (ABBV) shares. Going by data provided on Jun 29, 2023, Vanguard Total Stock Market Index Fund holds roughly 55.03 million shares. This is just over 3.12% of the total shares, with a market valuation of $7.41 billion. Data from the same date shows that the other fund manager holds a little less at 42.01 million, or 2.38% of the shares, all valued at about 5.66 billion.
